HUP0200223A3 - Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors and pharmaceutical compositions containing them - Google Patents
Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors and pharmaceutical compositions containing themInfo
- Publication number
- HUP0200223A3 HUP0200223A3 HU0200223A HUP0200223A HUP0200223A3 HU P0200223 A3 HUP0200223 A3 HU P0200223A3 HU 0200223 A HU0200223 A HU 0200223A HU P0200223 A HUP0200223 A HU P0200223A HU P0200223 A3 HUP0200223 A3 HU P0200223A3
- Authority
- HU
- Hungary
- Prior art keywords
- inhibitors
- tace
- mmp
- tnf
- preparation
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title 1
- 102000043279 ADAM17 Human genes 0.000 title 1
- 108091007505 ADAM17 Proteins 0.000 title 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 title 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 125000000304 alkynyl group Chemical group 0.000 title 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23803899A | 1999-01-27 | 1999-01-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0200223A2 HUP0200223A2 (en) | 2002-06-29 |
| HUP0200223A3 true HUP0200223A3 (en) | 2002-12-28 |
Family
ID=22896246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0200223A HUP0200223A3 (en) | 1999-01-27 | 2000-01-27 | Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors and pharmaceutical compositions containing them |
Country Status (13)
| Country | Link |
|---|---|
| JP (1) | JP2002535390A (cs) |
| KR (1) | KR20010101732A (cs) |
| AR (1) | AR035312A1 (cs) |
| AT (1) | ATE309986T1 (cs) |
| AU (1) | AU769418B2 (cs) |
| CA (1) | CA2356313A1 (cs) |
| CZ (1) | CZ20012711A3 (cs) |
| DE (1) | DE60024056D1 (cs) |
| EA (1) | EA200100806A1 (cs) |
| HU (1) | HUP0200223A3 (cs) |
| IL (1) | IL144345A0 (cs) |
| NZ (1) | NZ512566A (cs) |
| ZA (1) | ZA200105222B (cs) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004060875A1 (ja) * | 2002-12-26 | 2004-07-22 | Carna Biosciences Inc. | アルキニル基置換アザ糖誘導体およびそれを有効成分とする薬剤 |
| KR20090042779A (ko) * | 2006-06-30 | 2009-04-30 | 쉐링 코포레이션 | Ｐ53 활성을 증가시키는 치환된 피페리딘 및 이의 사용 |
| CA2724887A1 (en) * | 2008-06-02 | 2009-12-10 | Cipla Limited | Processes for the synthesis of levocetirizine and intermediates for use therein |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000075809A (ko) * | 1997-02-27 | 2000-12-26 | 윌리암 에이취 캘넌, 에곤 이 버그 | 매트릭스 메탈로프로테이나제 억제제로서의 ｎ-하이드록시-2-(알킬, 아릴 또는 헤테로아릴 설파닐, 설피닐 또는 설포닐)-3-치환된 알킬, 아릴 또는 헤테로아릴아미드 |
| IL137566A0 (en) * | 1998-02-19 | 2001-07-24 | American Cyanamid Co | N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
-
2000
- 2000-01-26 AR ARP000100327A patent/AR035312A1/es not_active Application Discontinuation
- 2000-01-27 AU AU26305/00A patent/AU769418B2/en not_active Ceased
- 2000-01-27 JP JP2000595979A patent/JP2002535390A/ja active Pending
- 2000-01-27 IL IL14434500A patent/IL144345A0/xx unknown
- 2000-01-27 AT AT00904569T patent/ATE309986T1/de not_active IP Right Cessation
- 2000-01-27 DE DE60024056T patent/DE60024056D1/de not_active Expired - Lifetime
- 2000-01-27 HU HU0200223A patent/HUP0200223A3/hu unknown
- 2000-01-27 KR KR1020017009432A patent/KR20010101732A/ko not_active Application Discontinuation
- 2000-01-27 EA EA200100806A patent/EA200100806A1/ru unknown
- 2000-01-27 NZ NZ512566A patent/NZ512566A/xx unknown
- 2000-01-27 CA CA002356313A patent/CA2356313A1/en not_active Abandoned
- 2000-01-27 CZ CZ20012711A patent/CZ20012711A3/cs unknown
-
2001
- 2001-06-25 ZA ZA200105222A patent/ZA200105222B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0200223A2 (en) | 2002-06-29 |
| EA200100806A1 (ru) | 2002-08-29 |
| AU769418B2 (en) | 2004-01-29 |
| ZA200105222B (en) | 2002-09-25 |
| AR035312A1 (es) | 2004-05-12 |
| JP2002535390A (ja) | 2002-10-22 |
| CA2356313A1 (en) | 2000-08-03 |
| KR20010101732A (ko) | 2001-11-14 |
| NZ512566A (en) | 2004-02-27 |
| ATE309986T1 (de) | 2005-12-15 |
| CZ20012711A3 (cs) | 2002-05-15 |
| DE60024056D1 (de) | 2005-12-22 |
| IL144345A0 (en) | 2002-05-23 |
| AU2630500A (en) | 2000-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0000641A3 (en) | Ortho-sulfonamido aryl hydroxamic acid derivatives, their use, as matrix metalloproteinase and tace inhibitors and pharmaceutical compositions containing them | |
| HUP0402263A3 (en) | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors, process for their preparation and pharmaceutical compositions containing them | |
| AU2002357312A1 (en) | Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases | |
| HUP0201680A3 (en) | Aromatic sulfone hydroxamic acid derivatives metalloprotease inhibitors and pharmaceutical compositions containing them | |
| IL136300A0 (en) | Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors | |
| HUP0103344A2 (hu) | Aril-piperazinok és felhasználásuk metalloproteináz-gátló anyagokként, eljárás előállításukra és ezeket tartalmazó gyógyászati készítmények | |
| HUP0201214A3 (en) | Inhibitors of impdh enzyme, pharmaceutical compositions containing them and their use | |
| HUP0300195A3 (en) | Heterocyclic sodium/proton exchange inhibitors and pharmaceutical compositions containing them | |
| HUP0200347A3 (en) | N-cyanomethylamides as protease inhibitors, pharmaceutical compositions containing them and their use | |
| HUP0103452A3 (en) | Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors and pharmaceutical compositions containing the compounds | |
| AU2002341715A1 (en) | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) | |
| AU2003220401A8 (en) | Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases | |
| HK1045501A1 (zh) | 作為基質金屬蛋白酶抑制劑的異羥肟酸衍生物 | |
| AU6764400A (en) | Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors | |
| HUP0200213A2 (en) | Alkynyl containing hydroxamic acid compounds as tace inhibitors, process for their preparation and pharmaceutical compositions containing them | |
| NO20013678D0 (no) | Alkynyl-holdige hydroksamsyre-derivater, deres fremstilling og deres anvendelse sommatriksmetalloproteinase(MMP)inhibitorer/TNF-<alfa>-konverteringsenzym(TACE)inhibitorer | |
| HUP0101899A3 (en) | Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes, pharmaceutical compositions comprising thereof and their use | |
| AU2002346729A1 (en) | Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases | |
| HUP0200223A3 (en) | Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors and pharmaceutical compositions containing them | |
| AU2201701A (en) | Hydroxamic acid derivatives as matrix metalloproteinase (mmp) inhibitors | |
| HUP0003880A3 (en) | Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors, pharmaceutical compositions thereof and process for the preparation of the same | |
| HUP0203118A3 (en) | Beta disubstituted metalloprotease inhibitors, pharmaceutical compositions containing them and their use | |
| HUP0200729A3 (en) | Hydroxamic acid derivatives, their use and preparation and pharmaceutical compositions containing them | |
| HUP0203270A3 (en) | Hydroxamic acid derivative as inhibitor of the formation of human cd23, process for its preparation and pharmaceutical compositions containing the same | |
| HUP0200605A3 (en) | Hydroxamic acid derivatives, their preparation and use and pharmaceutical compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |